ADVANTAGES OF FIXED-DOSE COMBINATION (FDC) PRODUCTS OVER LOOSE DOSE COMBINATION (LDC) PRODUCTS: A SYSTEMATIC LITERATURE REVIEW (SLR)

被引：0
|
作者：
Paoli, C. [1 ]
Tran, J. [2 ]
Winberg, D. [1 ]
Grieve, S. [3 ]
Thakur, D. [4 ]
Wyckmans, J. [5 ]
Linder, J. [6 ]
Gurjar, K. [4 ]
机构：
[1] Janssen Sci Affairs Inc, Titusville, NJ USA
[2] Cytel Inc, Waltham, MA USA
[3] Cytel Inc, Montreal, PQ, Canada
[4] Cytel Inc, Toronto, ON, Canada
[5] Janssen Pharmaceut Co Johnson & Johnson, Basel, Switzerland
[6] Janssen Cilag GmbH, Neuss, Germany
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCR45
引用
收藏
页码：S320 / S320
页数：1
相关论文
共 50 条
  • [1] Advantages of Efficacy and Safety of Fixed-Dose Tafluprost/Timolol Combination Over Fixed-Dose Latanoprost/Timolol Combination
    Fuwa, Masahiro
    Ueda, Kenji
    Akaishi, Takahiro
    Yamashita, Naoko
    Kirihara, Tomoko
    Shimazaki, Atsushi
    Mano, Hidetoshi
    Kawazu, Kouichi
    PLOS ONE, 2016, 11 (07):
  • [2] Mapping Advantages and Challenges in Analytical Development for Fixed Dose Combination Products, a Review
    Sen, Sibu
    Ganta, Brundharika
    Rachel, V. Nina
    Gogikar, Shiva Kumar
    Singh, Vartika
    Sonti, Rajesh
    Dikundwar, Amol G.
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2024, 113 (08) : 2028 - 2043
  • [3] Development status of fixed-dose combination finished pharmaceutical products
    Chen, Li-na
    Yuan, Bing-xiang
    ACTA PHARMACOLOGICA SINICA, 2013, 34 : 43 - 43
  • [4] Challenges and Opportunities in Achieving Bioequivalence for Fixed-Dose Combination Products
    Mitra, Amitava
    Wu, Yunhui
    AAPS JOURNAL, 2012, 14 (03): : 646 - 655
  • [5] Challenges and Opportunities in Achieving Bioequivalence for Fixed-Dose Combination Products
    Amitava Mitra
    Yunhui Wu
    The AAPS Journal, 2012, 14 : 646 - 655
  • [6] BIOPHARMACEUTIC STRATEGY FOR DEVELOPING A FIXED-DOSE COMBINATION (FDC) PRODUCT.
    Zhu, T.
    Awni, W.
    Locke, C.
    Wang, Y.
    Tang, E.
    Williams, L.
    Heneghan, G.
    Pradhan, R.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 : S27 - S27
  • [7] DEVELOPMENT OF ORALLY ADMINISTERED FIXED DOSE COMBINATION (FDC) PRODUCTS: PHARMACOKINETIC AND BIOPHARMACEUTICAL CONSIDERATIONS
    Kota, Jagannath
    Ayalavajjala, Phaninatha Sarma
    Sivasubramanian, Rama
    INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH, 2015, 6 (08): : 3161 - 3173
  • [8] Bioequivalence of fixed-dose combination RIN®-150 to each reference drug in loose combination
    Wang, H. F.
    Wang, R.
    O'Gorman, M.
    Crownover, P.
    Damle, B.
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2015, 19 (03) : 333 - 338
  • [9] Bioequivalence of fixed-dose combination Myrin®-P Forte and reference drugs in loose combination
    Wang, H. F.
    Wang, R.
    O'Gorman, M.
    Crownover, P.
    Naqvi, A.
    Jafri, I.
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2013, 17 (12) : 1596 - 1601
  • [10] Bioequivalence challenges in development of fixed-dose combination products: looking beyond reformulation
    Dubey, Rajesh
    EXPERT OPINION ON DRUG DELIVERY, 2012, 9 (03) : 325 - 332
12345